Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for KRYS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2016. Start Trial.
Date Value
June 30, 2026 74.79M
March 31, 2026 80.38M
December 31, 2025 77.51M
September 30, 2025 39.66M
June 30, 2025 52.73M
March 31, 2025 30.97M
December 31, 2024 52.84M
September 30, 2024 58.86M
June 30, 2024 -4.168M
March 31, 2024 15.89M
December 31, 2023 -7.232M
September 30, 2023 -21.23M
June 30, 2023 -34.19M
March 31, 2023 -26.16M
December 31, 2022 -22.33M
September 30, 2022 -19.69M
June 30, 2022 -43.06M
March 31, 2022 -15.49M
December 31, 2021 -20.90M
September 30, 2021 -7.255M
June 30, 2021 -10.13M
Date Value
March 31, 2021 -9.654M
December 31, 2020 -8.024M
September 30, 2020 -6.766M
June 30, 2020 -5.066M
March 31, 2020 -6.227M
December 31, 2019 -7.046M
September 30, 2019 -4.243M
June 30, 2019 -4.209M
March 31, 2019 -3.215M
December 31, 2018 -3.518M
September 30, 2018 -1.94M
June 30, 2018 -1.618M
March 31, 2018 -2.369M
December 31, 2017 -2.127M
September 30, 2017 -1.098M
June 30, 2017 -0.408M
March 31, 2017 -0.257M
December 31, 2016 -0.861M
September 30, 2016 -0.311M
June 30, 2016 -0.139M
March 31, 2016 0.00

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Marker Therapeutics, Inc. -3.716M
TG Therapeutics, Inc. 39.26M
Tenaya Therapeutics, Inc. -3.552M
Cytokinetics, Inc. -159.84M
Vericel Corp. 16.19M